PortfoliosLab logoPortfoliosLab logo
NVS vs. EQNR
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

NVS vs. EQNR - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Novartis AG (NVS) and Equinor ASA (EQNR). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, NVS achieves a 7.24% return, which is significantly lower than EQNR's 63.85% return.


NVS

1D
-1.51%
1M
-2.11%
YTD
7.24%
6M
11.77%
1Y
26.69%
3Y*
17.18%
5Y*
14.14%
10Y*
9.83%

EQNR

1D
1.34%
1M
-3.79%
YTD
63.85%
6M
69.88%
1Y
64.14%
3Y*
22.65%
5Y*
19.29%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

NVS vs. EQNR - Yearly Performance Comparison


2026 (YTD)20252024202320222021202020192018
NVS
Novartis AG
7.24%46.95%0.02%16.14%8.06%-3.65%3.34%13.92%10.58%
EQNR
Equinor ASA
63.85%7.70%-15.98%-0.78%40.77%64.55%-13.57%-0.99%-21.06%

Correlation

The correlation between NVS and EQNR is -0.09, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

-0.09

Correlation (3Y)
Calculated over the trailing 3-year period

0.06

Correlation (5Y)
Calculated over the trailing 5-year period

0.09

Correlation (All Time)
Calculated using the full available price history since May 17, 2018

0.17

The correlation between NVS and EQNR shifts across timeframes, from -0.09 (1 year) to 0.17 (all time), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap

NVS:

$274.91B

EQNR:

$94.66B

EPS

NVS:

$6.99

EQNR:

$2.15

PE Ratio

NVS:

20.53

EQNR:

17.61

PEG Ratio

NVS:

1.39

EQNR:

0.55

PS Ratio

NVS:

4.96

EQNR:

0.93

PB Ratio

NVS:

7.14

EQNR:

2.17

Total Revenue (TTM)

NVS:

$56.05B

EQNR:

$104.23B

Gross Profit (TTM)

NVS:

$42.19B

EQNR:

$36.46B

EBITDA (TTM)

NVS:

$22.40B

EQNR:

$39.36B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

NVS vs. EQNR — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

NVS
NVS Risk / Return Rank: 7575
Overall Rank
NVS Sharpe Ratio Rank: 7878
Sharpe Ratio Rank
NVS Sortino Ratio Rank: 7373
Sortino Ratio Rank
NVS Omega Ratio Rank: 7070
Omega Ratio Rank
NVS Calmar Ratio Rank: 7676
Calmar Ratio Rank
NVS Martin Ratio Rank: 7777
Martin Ratio Rank

EQNR
EQNR Risk / Return Rank: 8282
Overall Rank
EQNR Sharpe Ratio Rank: 8585
Sharpe Ratio Rank
EQNR Sortino Ratio Rank: 7979
Sortino Ratio Rank
EQNR Omega Ratio Rank: 7979
Omega Ratio Rank
EQNR Calmar Ratio Rank: 8787
Calmar Ratio Rank
EQNR Martin Ratio Rank: 8080
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

NVS vs. EQNR - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Novartis AG (NVS) and Equinor ASA (EQNR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


NVSEQNRDifference

Sharpe ratio

Return per unit of total volatility

1.32

1.80

-0.48

Sortino ratio

Return per unit of downside risk

1.88

2.29

-0.41

Omega ratio

Gain probability vs. loss probability

1.23

1.30

-0.07

Calmar ratio

Return relative to maximum drawdown

2.19

3.95

-1.76

Martin ratio

Return relative to average drawdown

5.58

6.85

-1.28

NVS vs. EQNR - Sharpe Ratio Comparison

The current NVS Sharpe Ratio is 1.32, which is comparable to the EQNR Sharpe Ratio of 1.80. The chart below compares the historical Sharpe Ratios of NVS and EQNR, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


NVSEQNRDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

1.32

1.80

-0.48

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.76

0.57

+0.18

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.50

Sharpe Ratio (All Time)

Calculated using the full available price history

0.42

0.30

+0.11

Drawdowns

NVS vs. EQNR - Drawdown Comparison

The maximum NVS drawdown since its inception was -42.10%, smaller than the maximum EQNR drawdown of -66.77%. Use the drawdown chart below to compare losses from any high point for NVS and EQNR.


Loading charts...

Drawdown Indicators


NVSEQNRDifference

Max Drawdown

Largest peak-to-trough decline

-42.10%

-66.77%

+24.67%

Max Drawdown (1Y)

Largest decline over 1 year

-12.65%

-17.72%

+5.07%

Max Drawdown (3Y)

Largest decline over 3 years

-19.95%

-27.58%

+7.63%

Max Drawdown (5Y)

Largest decline over 5 years

-20.42%

-35.50%

+15.08%

Max Drawdown (10Y)

Largest decline over 10 years

-26.03%

Current Drawdown

Current decline from peak

-12.32%

-9.89%

-2.43%

Average Drawdown

Average peak-to-trough decline

-10.93%

-21.51%

+10.58%

Ulcer Index

Depth and duration of drawdowns from previous peaks

4.97%

10.21%

-5.24%

Volatility

NVS vs. EQNR - Volatility Comparison

The current volatility for Novartis AG (NVS) is 5.77%, while Equinor ASA (EQNR) has a volatility of 14.18%. This indicates that NVS experiences smaller price fluctuations and is considered to be less risky than EQNR based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


NVSEQNRDifference

Volatility (1M)

Calculated over the trailing 1-month period

5.77%

14.18%

-8.41%

Volatility (6M)

Calculated over the trailing 6-month period

14.30%

29.64%

-15.34%

Volatility (1Y)

Calculated over the trailing 1-year period

20.29%

35.97%

-15.68%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

18.78%

33.84%

-15.06%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

19.59%

36.29%

-16.70%

Dividends

NVS vs. EQNR - Dividend Comparison

NVS's dividend yield for the trailing twelve months is around 3.33%, less than EQNR's 3.97% yield.


PositionTTM20252024202320222021202020192018201720162015
EQNR
Equinor ASA
3.97%7.66%12.66%11.38%3.30%2.13%4.32%5.07%3.26%0.00%0.00%0.00%
NVS
Novartis AG
3.33%2.90%3.84%3.44%3.70%3.86%3.22%3.03%3.47%3.24%3.73%3.10%

Financials

NVS vs. EQNR - Financials Comparison

This section allows you to compare key financial metrics between Novartis AG and Equinor ASA. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


10.00B15.00B20.00B25.00B30.00B35.00B40.00B45.00B20222023202420252026
13.52B
27.82B
(NVS) Total Revenue
(EQNR) Total Revenue
Values in USD except per share items

NVS vs. EQNR - Profitability Comparison

The chart below illustrates the profitability comparison between Novartis AG and Equinor ASA over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

30.0%40.0%50.0%60.0%70.0%80.0%20222023202420252026
74.4%
44.3%
Portfolio components
NVS - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Novartis AG reported a gross profit of 10.07B and revenue of 13.52B. Therefore, the gross margin over that period was 74.4%.

EQNR - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Equinor ASA reported a gross profit of 12.33B and revenue of 27.82B. Therefore, the gross margin over that period was 44.3%.

NVS - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Novartis AG reported an operating income of 4.24B and revenue of 13.52B, resulting in an operating margin of 31.3%.

EQNR - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Equinor ASA reported an operating income of 8.80B and revenue of 27.82B, resulting in an operating margin of 31.7%.

NVS - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Novartis AG reported a net income of 3.16B and revenue of 13.52B, resulting in a net margin of 23.3%.

EQNR - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Equinor ASA reported a net income of 3.11B and revenue of 27.82B, resulting in a net margin of 11.2%.


Frequently Asked Questions


NVS and EQNR have a correlation of -0.09, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

EQNR has higher volatility (14.18%) compared to NVS (5.77%). In terms of maximum drawdown, NVS dropped -42.10% vs EQNR's -66.77%.

EQNR currently has the higher Sharpe Ratio (1.80 vs 1.32), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for NVS and EQNR

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer